A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with kawasaki disease

Journal of Pediatrics

Volumn 143, Issue 3, 2003, Pages 357-362

  Nishimura, Shinji ^b   Zaitsu, Masafumi ^a   Hara, Megumi ^b   Yokota, Goro ^b   Watanabe, Mamie ^b   Jeda, Yoshiaki ^b   Imayoshi, Miyoko ^b   Ishii, Eiichi ^b   Tasaki, Hakaru ^b   Hamasaki, Yuhei ^b  

^a SAGA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; DNA; IMMUNOGLOBULIN; VASCULOTROPIN;

ALLELE; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION SITE;

EID: 0141615869     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0022-3476(03)00330-5     Document Type: Article

References (43)

1. Kawasaki T, Kosaki F, Okawa S, Shlgematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
2. Yanagawa H, Nakamura Y, Yashiro M, Oki I, Hirata S, Zhang T, et al. Incidence survey of Kasasaki disease in 1997 and 1998 in Japan. Pediatrics 2001;107:e33.
3. Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, et al. Selective expansion of T cells expressing T-cell receptor variable regions V β2 and V β8 in Kawasaki disease. Proc Natl Acad Sci U S A 1992;89:4066-70.
4. Leung DY, Giorno RC, Kazemi LV, Flynn PA, Busse JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995;155:5018-21.
5. Yoshioka T, Matsutani T, Iwagami S, Toyosaki-Maeda T, Yutsudo T, Tsuruta Y, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology 1999;96:465-72.
6. Katayama K, Matsubara T, Fujiwara M, Koga M, Furukawa S. CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin Exp Immunol 2000;121:566-70.
7. Takeshita S, Nakatani K, Tsujimoto H, Kawamura Y, Kawase H, Sekine I. Increased levels of circulating soluble CD14 in Kawasaki disease. Clin Exp Immunol 2000;119:376-81.
8. Takeshita S, Nakatani K, Kawase H, Seki S, Yamamoto M, Sekine I, et al. The role of bacterial lipopolysaccharide-bound neutrophils in the pathogenesis of Kawasaki disease. J Infect Dis 1999;179:508-12.
9. Furukawa S, Matsubara T, Okumura K, Yabuta K. Decreased expression of CD23 on peripheral blood macrophages/monocytes during acute Kawasaki disease with coronary artery lesions. Int Arch Allergy Immunol 1993;102:335-9.
10. Ariga S, Koga M, Takahashi M, Ishihara T, Matsubara T, Furukawa S. Maturation of macrophages from peripheral blood monocytes in Kawasaki disease: immunocytochemical and immunoelectron microscopic study. Pathol Int 2001;51:257-63.
11. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001;99:373-7.
12. Unkelbach K, Gardemann A, Kostrzewa M, Phillpp M, Tillmanns H, Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotlc risk profile. Arterioscler Thromb Vasc Biol 1999;19:932-8.
13. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin. E Am J Respir Cell Mol Biol 1999;20:976-83.
14. Koppelman GH, Reijmerink NE, Colin Stine O, Howard TD, Whittaker PA, Meyers DA, et al. Association of a promoter polymorphism of the CD14 gene and atopy. 2001;163:965-9.
15. Macmahon B, Trichopoulos D. Epidermiology: principles and methods 2nd ed. Boston (MA): Little, Brown and Co; 1996.
16. Hamamichi Y, Ichida F, Yu X, Hirono KI, Uese KI, Hashimoto I, et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res 2001;49:74-80.
17. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80.
18. Schiller B, Elinder G. Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment. Acta Paediatr 1999;88:844-8.
19. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin-2 receptor, and interferon-γ in Kawasaki disease-involved coronary artery lesions. Clin Immunol Immunopathol 1990;56:29-36.
20. Lin CY, Lin CC, Hwang B, Chiang BN. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr 1993;152:309-12.
21. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998;44:596-9.
22. Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999;83:337-9.
23. Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, et al. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2002;161:105-11.
24. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8.
25. Koga M, Ishihara T, Takahashi M, Umezawa Y, Furukawa S. Activation of peripheral blood monocytes and macrophages in Kawasaki disease: ultrastructural and immunocytochemical investigation. Pathol Int 1998;48:512-7.
26. Liao W. Endotoxin: possible roles in initiation and development of atherosclerosis. J Lab Clin Med 1996;128:452-60.
27. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, et al. C(-260) > T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999;99:3218-20.
28. Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H. Common polymorphism in the promoter of the CD14 monocle receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000;86:682-4.
29. Vercelli D, Baldini M, Martinez F. The monocyte/IgE connection: may polymorphisms in the CD14 gene teach us about IgE regulation? Int Arch Allergy Immunol 2001;124:20-4.
30. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
31. Uchimura E, Watanabe N, Kobayashi Y. Modulation by lipopolysaccharide of inflammatory cytokine production by two T cell lines. Cytokine 1997;9:727-33.
32. Eggesbo JB, Hjermann I, Lund PK, Joo GB, Ovstebo R, Kierulf P. LPS-induced release of IL-1 β, IL-6, IL-8, TNF-α, and sCD14 in whole blood and PBMC from persons with high or low levels of HD-lipoprotein. Cytokine 1994;6:521-9.
33. Hunt JS, Soares MJ, Lei MG, Smith RN, Wheaton D, Atherton RA, et al. Products of lipopolysaccharide-activated macrophages (tumor necrosis factor-α, transforming growth factor-β) but not lipopolysaccharide modify DNA synthesis by rat trophoblast cells exhibiting the 80-kDa lipopolysaccharide-binding protein. J Immunol 1989;143:1606-13.
34. Kato K, Yokoi T, Takano N, Kanegane H, Yachie A, Miyawaki T, et al. Detection by in situ hybridization and phenotypic characterization of cells expressing IL-6 mRNA in human stimulated blood. J Immunol 1990;144:1317-22.
35. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989;2:1298-302.
36. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor-α among patients with Kawasaki disease. J Pediatr 1992;121:924-6.
37. Barron KS, Montalvo JF, Joseph AK, Hilario MO, Saadeh C, Giannini EH, et al. Soluble interleukin-2 receptors in children with Kawasaki syndrome. Arthritis Rheum 1990;33:1371-7.
38. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001;167:5838-44.
39. Hayden CM, Goldblatt J, LeSouef PN. A novel polymorphism (g1344G > C) in exon 2 of the CD14 gene. Hum Mutat 2000;15:122.
40. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13:437-57.
41. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998;95:588-93.
42. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-92.
43. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001;276:21129-35.